iSpecimen Inc (ISPC)

NASD · Healthcare · Diagnostics & Research · USA

iSpecimen Inc is a micro cap company (market value under $300 million) in the Diagnostics & Research industry.

iSpecimen operates a global marketplace platform connecting life science researchers with healthcare providers who have human biospecimens and associated patient data. The platform enables researchers across industry, academia, and government to search and procure tissues, cells, and biofluids for their research, while providing healthcare providers with access to a broad researcher base.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the iSpecimen Inc stock.

Our verdict on ISPC

Overvalued: intrinsic value $0.20 per share, market price $0.60, margin of safety -193.3% (as of 2026-11-17).

Its liquidation floor, current assets minus every liability, values the shares at $0.20; the price of $0.60 is 193% above that value.

ETFs with the most weight in ISPC

More on ISPC

Browse

Peers in Diagnostics & Research

All 44 Diagnostics & Research stocks

Cheaper than ISPC in Diagnostics & Research

14 more in this industry show a wider margin of safety.

Is ISPC undervalued or overvalued?

ISPC is overvalued (as of the 2026-11-17 close). Its liquidation floor, current assets minus every liability, values the shares at $0.20; the price of $0.60 is 193% above that value.

What is the intrinsic value of ISPC?

$0.20 per share (as of the 2026-11-17 close), against a market price of $0.60. That is a margin of safety of -193.3%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.